|Assessment Status||Rapid review complete|
|Indication||For the treatment of non-neurological manifestations of MPS VII.|
|Rapid review commissioned||09/04/2019|
|Rapid review completed||22/05/2019|
|Rapid review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of vestronidase alfa compared with the current standard of care.|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.